-

$undefined

N/A

(N/A)

Oramed Pharmaceuticals NASDAQ:ORMP Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsulefor the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

Location: 1185 Avenue Of The Americas, 3Rd Floor, New York, 10036, US | Website: www.oramed.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-56.12M

Cash

142.3M

Avg Qtr Burn

-1.98M

Short % of Float

0.72%

Insider Ownership

13.64%

Institutional Own.

19.13%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORMD-0801 (ORA-D-013-1) Details Diabetes, Type 2 diabetes	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORMD-0801 Details Non-alcoholic steatohepatitis , Liver disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.